News

The data from ORAL Start (A3921069), a 24-month Phase 3 randomized trail conducted in methotrexate (MTX)-naïve patients with moderately to severely active RA is included in the sNDA.

Vedolizumab is indicated for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC), the two most common types of inflammatory bowel

Following approval, the medicine will be available in store with no age or point-of-sale restrictions, and consumers will not have to present their identification for purchasing the medicine.

According to the deal, a joint development committee with representatives from both the companies will look after AzaSite Xtra development and regulatory submission activities in the US and

LabCorp chief medical officer Dr Mark Brecher said, "MCM is a leading diagnostic laboratory and central lab in Japan with considerable experience and long-standing relationships in the medical

With a dual mechanism of action, the bactericidal, once-daily, injectable lipoglycopeptide antibiotic inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function. The product is indicated for

Biotech CEO Jason Cranford said, "Partnering with KannaLife Sciences opens up a window to establishing industry standards for phyto-medical products which includes providing certification, quality control and quality

ALX-0761 is the first clinical nanobody candidate resulting from the collaboration between the companies, which began in 2008. Commencement of the single-center, placebo-controlled trial, which is designed to

With original brand name of BI·Sifrol 0.125mg, 0.5mg tablets, Pramipexole hydrochloride 0.125mg tablets DSEP and Pramipexole hydrochloride 0.5mg tablets DSEP are dopamine agonists indicated for the treatment of